Association between pncA gene mutations, pyrazinamidase activity, and pyrazinamide susceptibility testing in Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 8, 2014, Pages 4928-4930

  Aono, Akio ^a   Chikamatsu, Kinuyo ^a   Yamada, Hiroyuki ^a   Kato, Tomoko ^a,b   Mitarai, Satoshi ^a,b  

^a RESEARCH INSTITUTE OF TUBERCULOSIS   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDASE; PNCA PROTEIN, MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANT TUBERCULOSIS; MUTATION; MYCOBACTERIUM TUBERCULOSIS;

AMIDOHYDROLASES; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84905396707     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02394-14     Document Type: Article

References (17)

1. British Medical Research Council. 1986. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. East and Central African/British Medical Research Council Fifth Collaborative Study. Tubercle 67:5-15.
2. Heifets L, Lindholm-Levy P. 1992. Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am. Rev. Respir. Dis. 145:1223-1225. http://dx.doi.org/10.1164/ajrccm/145.5.1223.
3. Scorpio A, Zhang Y. 1996. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med. 2:662-667. http://dx.doi.org/10. 1038/nm0696-662.
4. Zhang Y, Permar S, Sun Z. 2002. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J. Med. Microbiol. 51:42-49.
5. McDermott W, Tompsett R. 1954. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am. Rev. Tuberc. 70:748-754.
6. Aono A, Hirano K, Hamasaki S, Abe C. 2002. Evaluation of BACTEC MGIT 960 PZA medium for susceptibility testing of Mycobacterium tuberculosis to pyrazinamide (PZA): compared with the results of pyrazinamidase assay and Kyokuto PZA test. Diagn. Microbiol. Infect. Dis. 44:347-352. http://dx.doi.org/10.1016/S0732-8893(02)00471-6.
7. Sekiguchi J, Tomohiko N, Tohru MA, Fumiko K, Intetsu K, Ewa AK, Zofia Z, Koji M, Toshinori S, Hiroshi Y, Seiya K, Toru M, Teruo K. 2007. Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis strains. J. Clin. Microbiol. 45:2802-2807. http://dx.doi.org/10.1128/JCM.00352-07.
8. Clinical and Laboratory Standards Institute. 2012. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard, 2nd ed. Document M24-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Louw GE, Warren RM, Donald PR, Murray MB, Bosman M, Van Helden PD, Young DB, Victor TC. 2006. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int. J. Tuberc. Lung Dis. 10:802-807.
10. Marttila HJ, Marjamaki M, Vyshnevskaya E, Vyshnevskiy BI, Otten TF, Vasilyef AV, Viljanen MK. 1999. pncA mutations in pyrazinamideresistant Mycobacterium tuberculosis isolates from northwestern Russia. Antimicrob. Agents Chemother. 43:1764-1766.
11. Werngren J, Sturegård E, Juréen P, Ängeby K, Hoffner S, Schön T. 2012. Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wildtype MIC distributions and pncA gene sequencing. Antimicrob. Agents Chemother. 56:1253-1257. http://dx.doi.org/10.1128/AAC.05894-11.
12. Wayne LG. 1974. Simple pyrazinamidase and urease tests for routine identification of mycobacteria. Am. Rev. Respir. Dis. 109:147-151.
13. Sreevatsan S, Pan X, Zhang Y, Kreiswirth BN, Musser JM. 1997. Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob. Agents Chemother. 41:636-640.
14. Supply P, Allix C, Lesjean S, Cardoso-Oelemann M, Rüsch-Gerdes S, Willery E, Savine E, de Haas P, van Deutekom H, Roring S, Bifani P, Kurepina N, Kreiswirth B, Sola C, Rastogi N, Vatin V, Gutierrez MC, Fauville M, Niemann S, Skuce R, Kremer K, Locht C, Soolingen D. 2006. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J. Clin. Microbiol. 44:4498-4510. http://dx.doi.org/10.1128/JCM.01392-06.
15. McClatchy JK, Tsang AY, Cernich MS. 1981. Use of pyrazinamidase activity on Mycobacterium tuberculosis as a rapid method for determination of pyrazinamide susceptibility. Antimicrob. Agents Chemother. 20:556-557. http://dx.doi.org/10.1128/AAC.20.4.556.
16. Shi W, Zhang X, Jiang X, Yuan H, Lee JS, Barry CE III, Wang H, Zhang W, Zhang Y. 2011. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 333:1630-1632. http://dx.doi.org/10.1126/science.1208813.
17. Sheen P, Lozano K, Gilman RH, Valencia HJ, Loli S, Fuentes P, Grandjean L, Zimic M. 2013. pncA gene expression and prediction factors on pyrazinamide resistance in Mycobacterium tuberculosis. Tuberculosis 93:515-522. http://dx.doi.org/10.1016/j.tube.2013.03.005.